BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 16989659)

  • 1. Common gene expression signatures in t(8;21)- and inv(16)-acute myeloid leukaemia.
    Ichikawa H; Tanabe K; Mizushima H; Hayashi Y; Mizutani S; Ishii E; Hongo T; Kikuchi A; Satake M
    Br J Haematol; 2006 Nov; 135(3):336-47. PubMed ID: 16989659
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias.
    Lo Coco F; Pisegna S; Diverio D
    Haematologica; 1997; 82(3):364-70. PubMed ID: 9234595
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A distinct epigenetic signature at targets of a leukemia protein.
    Rossetti S; Hoogeveen AT; Liang P; Stanciu C; van der Spek P; Sacchi N
    BMC Genomics; 2007 Feb; 8():38. PubMed ID: 17266773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pathogenesis of acute myeloid leukaemia and inv(16)(p13;q22): a paradigm for understanding leukaemogenesis?
    Reilly JT
    Br J Haematol; 2005 Jan; 128(1):18-34. PubMed ID: 15606546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discrimination of target by siRNA: designing of AML1-MTG8 fusion mRNA-specific siRNA sequences.
    Kasashima K; Sakota E; Kozu T
    Biochimie; 2004; 86(9-10):713-21. PubMed ID: 15556282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PRDX4, a member of the peroxiredoxin family, is fused to AML1 (RUNX1) in an acute myeloid leukemia patient with a t(X;21)(p22;q22).
    Zhang Y; Emmanuel N; Kamboj G; Chen J; Shurafa M; Van Dyke DL; Wiktor A; Rowley JD
    Genes Chromosomes Cancer; 2004 Aug; 40(4):365-70. PubMed ID: 15188461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of cytogenetic and molecular genetic detection of t(8;21) and inv(16) in a prospective series of adults with de novo acute myeloid leukemia: a Cancer and Leukemia Group B Study.
    Mrózek K; Prior TW; Edwards C; Marcucci G; Carroll AJ; Snyder PJ; Koduru PR; Theil KS; Pettenati MJ; Archer KJ; Caligiuri MA; Vardiman JW; Kolitz JE; Larson RA; Bloomfield CD
    J Clin Oncol; 2001 May; 19(9):2482-92. PubMed ID: 11331327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Williams-Beuren syndrome critical region-5/non-T-cell activation linker: a novel target gene of AML1/ETO.
    Fliegauf M; Stock M; Berg T; Lübbert M
    Oncogene; 2004 Dec; 23(56):9070-81. PubMed ID: 15489901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
    Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
    J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RAD51 and XRCC3 polymorphisms: impact on the risk and treatment outcomes of de novo inv(16) or t(16;16)/CBFβ-MYH11(+) acute myeloid leukemia.
    Liu L; Yang L; Mi Y; Wang J; Li J; Zhang Y; Ma X; Qin T; Xu Z; Xiao Z
    Leuk Res; 2011 Aug; 35(8):1020-6. PubMed ID: 21296419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias.
    Serrano E; Carnicer MJ; Lasa A; Orantes V; Pena J; Brunet S; Aventín A; Sierra J; Nomdedéu JF
    Leuk Res; 2008 Jun; 32(6):944-53. PubMed ID: 18206229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of the CBFB/MYH11 fusion gene in de novo acute myeloid leukemia (AML): a single-institution study of 224 Japanese AML patients.
    Monma F; Nishii K; Shiga J; Sugahara H; Lorenzo F; Watanabe Y; Kawakami K; Hosokai N; Yamamori S; Katayama N; Shiku H
    Leuk Res; 2007 Apr; 31(4):471-6. PubMed ID: 17052753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A rapid RT-PCR screening assay incorporating multiplexed validated control genes for CBF rearrangements at diagnosis in AML.
    Saal RJ; Marlton PV; Timson G; Gill DS; Waugh M; Springall F; Iland H
    Pathology; 2004 Aug; 36(4):335-42. PubMed ID: 15370133
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunohistochemical analysis of CBFbeta-SMMHC protein reveals a unique nuclear localization in acute myeloid leukemia with inv(16)(p13q22).
    Zhao W; Claxton DF; Medeiros LJ; Lu D; Vadhan-Raj S; Kantarjian HM; Nguyen MH; Bueso-Ramos CE
    Am J Surg Pathol; 2006 Nov; 30(11):1436-44. PubMed ID: 17063086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup.
    Prébet T; Boissel N; Reutenauer S; Thomas X; Delaunay J; Cahn JY; Pigneux A; Quesnel B; Witz F; Thépot S; Ugo V; Terre C; Recher C; Tavernier E; Hunault M; Esterni B; Castaigne S; Guilhot F; Dombret H; Vey N; ; ;
    J Clin Oncol; 2009 Oct; 27(28):4747-53. PubMed ID: 19720919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two more inv(16) acute myeloid leukemia cases with infrequent CBFbeta-MYH11 fusion transcript: clinical and molecular findings.
    Martinelli G; Ottaviani E; Buonamici S; Isidori A; Malagola M; Piccaluga P; Baccarani M
    Haematologica; 2002 May; 87(5):554-5. PubMed ID: 12010674
    [No Abstract]   [Full Text] [Related]  

  • 17. Promoter hypermethylation of the retinoic acid receptor beta2 gene is frequent in acute myeloid leukaemia and associated with the presence of CBFbeta-MYH11 fusion transcripts.
    Rethmeier A; Aggerholm A; Olesen LH; Juhl-Christensen C; Nyvold CG; Guldberg P; Hokland P
    Br J Haematol; 2006 May; 133(3):276-83. PubMed ID: 16643429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of WT1 gene expression in pediatric acute myeloid leukemia.
    Rodrigues PC; Oliveira SN; Viana MB; Matsuda EI; Nowill AE; Brandalise SR; Yunes JA
    Pediatr Blood Cancer; 2007 Aug; 49(2):133-8. PubMed ID: 16883592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression levels of TEL, AML1, and the fusion products TEL-AML1 and AML1-TEL versus drug sensitivity and clinical outcome in t(12;21)-positive pediatric acute lymphoblastic leukemia.
    Stams WA; den Boer ML; Beverloo HB; Meijerink JP; van Wering ER; Janka-Schaub GE; Pieters R
    Clin Cancer Res; 2005 Apr; 11(8):2974-80. PubMed ID: 15837750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miR-17 deregulates a core RUNX1-miRNA mechanism of CBF acute myeloid leukemia.
    Fischer J; Rossetti S; Datta A; Eng K; Beghini A; Sacchi N
    Mol Cancer; 2015 Jan; 14():7. PubMed ID: 25612891
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.